Abstract
Background and Aims: Elevated circulating triglycerides are a risk factor for coronary artery disease. As an inhibitor of lipoprotein lipase, Angiopoietin-like 4 (ANGPTL4) has therapeutic potential for correcting dyslipidaemia and associated coronary artery disease. Humans with loss-of-function mutations in ANGPTL4 have decreased levels of circulating triglycerides, as do Angptl4-/- mice. However, upon consumption of a high fat diet, the latter develop chylous ascites, a massive acute phase response and mesenteric lymphadenopathy characterized by the presence of giant lipid-laden macrophages.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
